The guidelines of the Kidney Disease Improving Global Outcomes (KDIGO) Foundation recommend angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are used as first-line agents for kidney-disease patients with hypertension because of their unique role in reducing glomerular hypertension beyond decreasing systemic blood pressure4. This evidence concerns the gene ACE and kidney disorder.